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In the search for safer, non-addictive analgesics, kappa opioid receptor (KOPr) agonists
are a potential target, as unlike mu-opioid analgesics, they do not have abuse potential.
Salvinorin A (SalA) is a potent and selective KOPr agonist, however, clinical utility is
limited by the short duration of action and aversive side effects. Biasing KOPr signaling
toward G-protein activation has been highlighted as a key cellular mechanism to reduce
the side effects of KOPr agonists. The present study investigated KOPr signaling bias
and the acute antinociceptive effects and side effects of two novel analogs of SalA,
16-Bromo SalA and 16-Ethynyl SalA. 16-Bromo SalA showed G-protein signaling bias,
whereas 16-Ethynyl SalA displayed balanced signaling properties. In the dose-response
tail-withdrawal assay, SalA, 16-Ethynyl SalA and 16-Bromo SalA were more potent than
the traditional KOPr agonist U50,488, and 16-Ethynyl SalA was more efficacious. 16Ethynyl SalA and 16-Bromo SalA both had a longer duration of action in the warm water
tail-withdrawal assay, and 16-Ethynyl had greater antinociceptive effect in the hot-plate
assay, compared to SalA. In the intraplantar 2% formaldehyde test, 16-Ethynyl SalA and
16-Bromo SalA significantly reduced both nociceptive and inflammatory pain-related
behaviors. Moreover, 16-Ethynyl SalA and 16-Bromo SalA had no anxiogenic effects in
the marble burying task, and 16-Bromo SalA did not alter behavior in the elevated zero
maze. Overall, 16-Ethynyl SalA significantly attenuated acute pain-related behaviors in
multiple preclinical models, while the biased KOPr agonist, 16-Bromo SalA, displayed
modest antinociceptive effects, and lacked anxiogenic effects.
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INTRODUCTION
Pain causes suffering and discomfort, often having profound effects on quality of life (Vartiainen
et al., 2016). To treat pain, medicines are prescribed that typically activate the mu-opioid receptor
(MOPr), such as morphine, codeine and fentanyl (Toblin et al., 2011). Unfortunately, chronic
treatment with MOPr agonists can potentiate pain (Celerier et al., 2000; Roeckel et al., 2016), and
lead to dependence and addiction (Compton and Volkow, 2006). Opioid overdoses are the leading
cause of accidental death in the United States (Okie, 2010; Rudd et al., 2016). Additionally, rates of
opioid overdose have also been rising globally (GBD 2017 Causes of Death Collaborators, 2018).
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16-Bromo SalA and 16-Ethynyl SalA attenuated drug-seeking
in cocaine prime-induced reinstatement without decreasing
spontaneous locomotor activity (Riley et al., 2014). To more fully
understand the potential therapeutic effects of these SalA analogs
and the involvement of KOPr signaling bias, the present study
compared the cell signaling pathways of 16-Ethynyl SalA and
16-Bromo SalA and assessed their antinociceptive effects and
side effect profiles in mice.

In contrast to MOPr agonists, kappa opioid receptor (KOPr)
agonists play a critical role in regulating the reward system
by contributing to the negative-feedback of dopamine (Di
Chiara and Imperato, 1988). Studies have shown that acute
administration of KOPr agonists show anti-addictive potential
and have antinociceptive (Gallantine and Meert, 2008), antiinflammatory (Binder et al., 2001; Bileviciute-Ljungar et al.,
2006), antipruritic effects (Kumagai et al., 2010; Akiyama et al.,
2015) and anticonvulsant and anti-seizure effects (Zangrandi
et al., 2016). In contrast to MOPr agonists, KOPr agonists do
not inhibit gastrointestinal transit (Porreca et al., 1984) or cause
respiratory depression (Freye et al., 1983).
Despite these advantages, traditional KOPr agonists, such as
U50,488, that have balanced signaling properties (Schattauer
et al., 2012), are associated with many side effects including
sedation, anxiety, aversion, and dysphoria limiting their clinical
development (Mucha and Herz, 1985; Pfeiffer et al., 1986; Suzuki
et al., 1992; Bals-Kubik et al., 1993; Privette and Terrian, 1995;
Pande et al., 1996; Skoubis et al., 2001; Walsh et al., 2001; Mague
et al., 2003; Kudryavtseva et al., 2004; Vunck et al., 2011; Ehrich
et al., 2015; Zhang et al., 2015; Wang et al., 2016). The concept
of biased agonism, whereby activation of a G-protein coupled
receptor can result in differential activation of signal transduction
pathways, suggests that it may be possible to separate desired
physiological effects from adverse side effects. This highlights
biased agonism as a potential characteristic that can be exploited
for therapeutic advantage. It has been suggested that KOPr
agonists that preferentially activate G-protein signaling pathways
over β-arrestin recruitment are likely to have reduced side effects
(Bruchas and Chavkin, 2010). In support of this concept, the only
clinically available KOPr agonist, nalfurafine, has recently been
shown to be extremely G-protein biased at the human KOPr
(hKOPr) (Schattauer et al., 2017). However, finding evidence in
support of G-protein biased agonism has proven more difficult
than anticipated, and some studies have found that nalfurafine is
a balanced agonist (Liu et al., 2019) or β-arrestin biased (Dunn
et al., 2019). Unfortunately, nalfurafine failed to alleviate painrelated depression of operant behavior in rats (Lazenka et al.,
2018), and failed in development as an analgesic candidate,
instead, it is now clinically available as an antipruritic drug in
Japan (Kumagai et al., 2010).
Salvinorin A (SalA) is a naturally occurring KOPr
agonist (Roth et al., 2002; Chavkin et al., 2004) with proven
antinociceptive and anti-inflammatory effects in vivo (Ansonoff
et al., 2006; John et al., 2006; McCurdy et al., 2006; Aviello et al.,
2011; Fichna et al., 2012; Guida et al., 2012; Simonson et al.,
2015; Rossi et al., 2016). However, a short duration of action
(Prisinzano, 2005; Butelman et al., 2009; Teksin et al., 2009;
Ranganathan et al., 2012), with aversive (Zhang et al., 2005) and
anxiogenic side effects (Braida et al., 2009), have limited the
clinical development of SalA. Therefore, the structure of SalA
has been altered in an attempt to develop G-protein biased KOPr
agonists with fewer side effects (White et al., 2015; Kivell et al.,
2018). Modifications have been made at the carbon-16 position
on the furan ring of SalA, with the addition of an ethynyl group
creating 16-Ethynyl SalA, and the addition of a bromine group
creating 16-Bromo SalA (Riley et al., 2014). Promisingly, in rats,
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MATERIALS AND METHODS
Drug Preparation
Salvinorin A was isolated and purified from Salvia divinorum
leaves and assessed for purity (>98%) using high-performance
liquid chromatography (HPLC). The SalA analogs, 16-Ethynyl
SalA and 16-Bromo SalA, were synthesized as previously
described (Riley et al., 2014) and were tested for purity (>95%)
with HPLC. Nor-binaltorphimine (nor-BNI) and U50,488 were
purchased from Sigma-Aldrich (St. Louis, MO, United States).

Cellular Assays
The forskolin-induced cyclic adenosine monophosphate (cAMP)
accumulation was measured in the HitHunterTM assay in
Chinese Hamster Ovary (CHO) cells stably expressing the
hKOPr (DiscoverX Corporation, Fremont, CA, United States)
as previously described (Riley et al., 2014). The β-arrestin2
recruitment assay was measured using the DiscoverX
PathHunterTM assay in U2OS cells stably expressing β-arrestin2
and hKOPr as previously described following the manufacturer’s
protocol (Kivell et al., 2018). The cAMP accumulation data
was normalized to the vehicle and forskolin-only controls. The
β-arrestin2 recruitment data was normalized to the vehicle and
U50,488 maximum response values. The following formula
was used to calculate the bias factor as previously described
(Crowley et al., 2016; Kivell et al., 2018), with U50,488 as the
reference ligand:
!
Emax(test) × EC50(control)

log bias factor = log
EC50(test) × Emax(control)
G−protein

− log

Emax(test) × EC50(control)
EC50(test) × Emax(control)

!
β−arrestin2

Using this formula, a bias factor of 1 is a balanced agonist
relative to U50,488, less than 1 is a β-arrestin2 biased agonist and
more than 1 is a G-protein biased agonist.

Animals
Adult male B6-SJL (20–30 g, 8 + weeks old) were used for
experimental procedures, except for the marble-burying and
elevated zero maze procedures which used male C57Bl/6J mice.
Animals were bred and housed at the Victoria University of
Wellington Animal Facility, New Zealand, however, breeding
stock animals were originally sourced from the Jackson
Laboratories (Bar Harbor, ME, United States). The animals were
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injections into the same area. At 30 min post-injection, the tailwithdrawal latency was measured and the next cumulative dose
administered immediately after. The doses of 16-Ethynyl SalA
and 16-Bromo SalA were delivered at: 0.3, 0.6, 1.0, 2.5, 5.0, 7.5,
10.0, and 12.5 mg/kg. Non-linear regression analysis was used to
determine potency [median effective dose (ED50 )] and efficacy
calculated by normalizing data to the prototype KOPr agonist
U50,488 [maximum dose achieved (Emax )].

group-housed (maximum five mice/cage) on a 12-h light/dark
cycle (lights on at 07:00) with a stable temperature (19–21◦ C)
and humidity (55%). All experimental procedures were carried
out in the light cycle. Food and water were provided ad libitum
except during experimental procedures. Animals were handled
for at least 2 days before testing to reduce handling stress. All
procedures were carried out with the approval of the Victoria
University of Wellington Animal Ethics Committee (approval
numbers 21480 and 25751). All procedures were carried out in
agreement with the New Zealand Animal Welfare Act, 1999.
All KOPr agonists were dissolved in a vehicle containing
DMSO, Tween-80 (Sigma-Aldrich) and physiological saline at a
ratio of 2:1:7, respectively. The KOPr agonists were delivered at a
volume of 10 µL/g of weight via intraperitoneal (i.p.) injection
and delivered at 5 µL/g via subcutaneous (s.c.) injection in
the warm water tail-withdrawal dose-response experiments. The
KOPr antagonist nor-BNI was dissolved in physiological saline
and injected s.c. 24 h prior to testing to selectively antagonize the
KOPr, as earlier pre-treatment intervals have been shown to also
antagonize the MOPr (Endoh et al., 1992; Kishioka et al., 2013).

Hot-Plate Assay
Mice were placed in a clear plastic enclosure positioned on a 50◦ C
hot-plate (IITC Life Science, Woodland Hills, CA, United States).
Timing began when all four paws were touching the hot-plate
and stopped when mice exhibited any of the following behaviors:
jumping or shaking/licking one of the hind paws. A cut-off time
of 30 s was used to avoid tissue damage. The baseline latency
was taken as the average of the three measurements, measured
once per day for 3 days prior to testing. On the test day, an i.p.
injection of the KOPr agonist or vehicle was administered and
measurements were taken at 15, 30, and 60 min post-injection.
The %MPE at each time point was calculated using the following
formula:


test latency−baseline latency
% MPE =
× 100
30 − baseline latency

Warm Water Tail-Withdrawal Assay
On the 2 days prior to the test day, mice were restrained in
transparent plastic tube restrainers (internal diameter 24 mm) for
5 min daily, to reduce restraint stress. Tail-withdrawal latencies
were measured by immersing one-third of the distal portion
of the tail in a warm water bath (50 ± 0.5◦ C) and the time
to show the withdrawal response recorded. A maximum tail
immersion cut-off of 10 s was used to avoid tissue damage and
allow for repeated exposure to the thermal stimulus. On the
day of the experiment, the baseline latency for each animal was
measured by averaging three predrug tail-withdrawal latencies,
with successive measurements taken at least 5 min apart.
Following the experimental procedure, the percentage maximum
possible effect (%MPE) was calculated for each animal at each
time point by using the following formula:

% MPE =

test latency−baseline latency
10 − baseline latency

Intraplantar 2% Formaldehyde Model
The Intraplantar 2% formaldehyde model was carried out as
previously described (Paton et al., 2017; Sherwood et al., 2017).
The custom-made chamber (27.5 × 18.5 cm) sat on a glass
surface with a 45◦ angle mirror underneath to capture the
behaviors via a video camera. The mice were habituated to the
test enclosure for 15 min before testing. The mice were given
KOPr agonist or vehicle treatment via i.p. injection 5 min prior to
the administration of 20 µL of formaldehyde (2% in PBS) or PBS
alone via intraplantar (i.pl.) injection. The animals were recorded
for 60 min. The methods of Dubuisson and Dennis (1977) were
used to assess the pain-like behavior using a weight-bearing score.
The pain-related behavior was scored as 0 if the mouse showed
normal behavior; (1) for partial weight-bearing with only the
digits touching the floor; (2) with no weight-bearing with the
paw raised; and (3) where the paw was bitten, licked or shaken.
Scores were assessed every 5 s and averaged for every 5 min time
period. For the area under the curve analysis, the two phases
were separated out as follows: 0–15 min phase one nociceptive
pain-related behavior; and 20–60 min phase two inflammatory
pain-related behavior.
To test the local effects of the compounds, treatments were
given as an i.pl. injection 5 min prior to and in the same hind
paw as the 2% formaldehyde i.pl. injection. The KOPr agonist or
vehicle were delivered at 1 µL/g with a maximum of 30 µL. The
KOPr agonists were in a vehicle containing DMSO only.


× 100

To measure the duration of action, the tail-withdrawal latencies
were measured over a time-course as previously described
(Simonson et al., 2015; Paton et al., 2017). Following the baseline
latency measurements, mice were given an i.p. injection of
either KOPr agonist or vehicle and the latency to tail-withdrawal
behavior determined at 5, 10, 15, 30, 45, 60, 90, and 120 min for
each animal in a repeated measures design.

Cumulative Dose-Response
Tail-Withdrawal Assay
The cumulative dose-response effects were evaluated using a
within animal design, as previously described (Bohn et al., 2000;
Paton et al., 2017; Sherwood et al., 2017). Briefly, mice were given
s.c. injections at increasing concentrations to create cumulative
doses in a volume of 5 µL/g of weight into the scruff of the neck,
the left flank and the right flank in sequence to avoid continuous
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Rotarod Performance Assay
Mice were assessed for motor coordination on an accelerating
rotarod apparatus with acceleration set from 4 to 40 rpm over
300 s (32 mm diameter barrel; Harvard Apparatus, Holliston,
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MA, United States) as previously described in Crowley et al.
(2016). The mice were trained on the apparatus in a series of
four sessions/day over 4 days and on test day, the latency to fall
from the apparatus was measured, with a maximum of 300 s.
On the test day, triplicate baseline measurements were taken and
only mice with latencies for longer than 240 s in every trial were
included in the experiment, to exclude any animals with preexisting motor incoordination. The mice were administered an
i.p. injection of either the KOPr agonist or vehicle and the latency
to fall was measured repeatedly at 15, 30, 45, 60, 90, 120, 180,
and 240 min. The results were expressed as a percentage of the
individual animal’s baseline.

was analyzed using one-way ANOVA followed by Bonferroni
post-test (parametric) or Kruskal–Wallis followed by Dunn’s
post-test (non-parametric). Comparisons of multiple effects over
time were analyzed using two-way repeated-measures ANOVA
followed by Bonferroni post-tests. The p values reported for the
post-tests were adjusted for multiple families of comparisons.

RESULTS
A 16-Ethynyl SalA and 16-Bromo SalA are analogs of SalA
with alterations at the C-16 position (Figure 1). To determine
the bias factor of the compounds, both the G-protein and βarrestin2 signaling pathways were measured. 16-Ethynyl SalA
and 16-Bromo SalA had higher potency (EC50 ) than U50,488
at inhibiting forskolin-induced cAMP accumulation (Figure 2A
and Table 1). The β-arrestin2 pathway was quantified using βarrestin2 recruitment assays and showed that 16-Ethynyl SalA
was more potent (EC50 ) than and 16-Bromo SalA and U50,488
(Figure 2B and Table 1). There were no significant differences in
the efficacy (Emax ) between any of the compounds in these assays.
The bias calculation revealed that 16-Bromo SalA was G-protein
biased, whereas 16-Ethynyl SalA was a balanced agonist (Table 1).
The warm water tail-withdrawal assay measures the spinal
reflex in response to a thermal stimulus. Non-linear regression
analysis was used to determine the potency (median effective
dose, ED50 ) and the efficacy (maximum response, Emax ,
Figure 3A) and the values were compared to the traditional
KOPr agonist, U50,488 (data set previously published in
Paton et al., 2017). The ED50 values showed 16-Ethynyl SalA
(ED50 = 1.54 mg/kg) and 16-Bromo SalA (ED50 = 2.06 mg/kg)
were significantly more potent when compared to U50,488
(ED50 = 6.28 mg/kg). The Emax values showed that only

Elevated Zero Maze
The elevated zero maze apparatus comprises a 5 cm wide elevated
circular track with a 40 cm internal diameter and a 2 mm
border. The maze is separated into four quadrants, two opposite
quadrants are enclosed by 16 cm high dark, opaque walls, and two
are open. Mice naïve to the maze were injected with either vehicle,
SalA, 16-Ethynyl SalA or 16-Bromo SalA and 10 min later placed
in the closed area of the apparatus. The mice were able to freely
move within the apparatus for 5 min with behavior recorded from
an overhead camera. The videos were assessed for time spent in
the open arm, the number of open arm entries, and head dips
over the edge of the open arm.

Marble Burying
Clean cages were set up containing 5 cm of fresh bedding with
20 marbles arranged in rows. The mice were injected i.p. with
either the KOPr agonist or vehicle and immediately placed in
the cage and left undisturbed for 30 min. A photo was taken of
each cage after the mouse was removed. Two observers who were
blind to the treatment groups assessed the images for the number
of marbles that remained unburied. Marbles were assigned as
buried if less than a third of the marble was visible. Marbles were
cleaned with 70% ethanol and autoclaved before being reused for
subsequent mice.

Data Analysis
GraphPad Prism (version 7.03, GraphPad Software, La Jolla,
CA, United States) was used to determine statistical significance.
Values represented as the mean ± standard error of the mean
(SEM) and were considered significant when p < 0.05. The data
sets were tested for normality using the D’Agostino and Pearson
omnibus normality test. Unpaired t-tests were used to compare
between two groups. Comparison of multiple treatment data

FIGURE 1 | Chemical structures of Salvinorin A, 16-Ethynyl Salvinorin A, and
16-Bromo Salvinorin A.

TABLE 1 | Functional activity and signaling bias of 16-Ethynyl SalA and 16-Bromo SalA in cAMP inhibition and β-arrestin recruitment assays.
β-arrestin2 recruitment

Inhibition of forskolin-induced cAMP accumulation
Compound

EC50 (nM)

logEC50 ± SEM

Emax ± SEM

EC50 (nM)

logEC50 ± SEM

Emax ± SEM

Bias factor

U50,488

0.111

−9.96 ± 0.073

100

84.9

−7.07 ± 0.084

100

1

16-Bromo SalA

0.035

−10.5 ± 0.059****

98.8 ± 1.84

212

−6.67 ± 0.298

102 ± 13.7

7.7 G

16-Ethynyl SalA

0.011

−11.0 ± 0.082****

101 ± 1.79

7.35

−8.13 ± 0.076***

89.0 ± 2.2

1.0

***p < 0.001, ****p < 0.0001 for comparisons to U50,488, analyzed using one-way ANOVA with Bonferroni post-tests.
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FIGURE 2 | The activity of U50,488, 16-Ethynyl SalA, and 16-Bromo SalA in the cyclic adenosine monophosphate (cAMP) and β-arrestin recruitment assays.
(A) The KOPr agonists were measured for inhibition of forskolin-induced cAMP (HitHunterTM ): U50,488 n = 29 across 11 experiments, 16-Ethynyl SalA n = 36 across
16 experiments, 16-Bromo SalA n = 18 across six experiments and (B) β-arrestin recruitment (PathHunterTM ): U50,488 n = 26 across nine experiments, 16-Ethynyl
SalA n = 12 across three experiments, 16-Bromo SalA n = 15 across five experiments. Values presented as mean ± SEM.

16-Ethynyl SalA (171.0 ± 21.5%) had a significantly higher
maximum effect than U50,488.
To measure the onset and duration of action of the
KOPr agonists, the warm water tail-withdrawal assay was used
following a single i.p. injection, and the tail-withdrawal latencies
measured over time. 16-Ethynyl SalA showed a significant
antinociceptive effect for the 1 mg/kg dose at 10–15 min and a
significant effect for the 2 mg/kg dose at 5–60 min (Figure 3B).
16-Bromo SalA showed significant antinociceptive effects at
1 mg/kg at 10–60 min and for the 2 mg/kg dose at 10–15 and
45–60 min (Figure 3C).
The hot-plate assay measures the withdrawal response from
a thermal stimulus to the paws, which involves supraspinal
processes. Similar to the previous experiment, the onset and
duration of action can be measured using this technique.
Bonferroni post-tests showed that SalA (2 mg/kg), 16-Bromo
SalA and 16-Ethynyl SalA had a duration of action of 30 min
(Figure 3D). In addition, at the 30 min time point, 16-Ethynyl
SalA had a greater antinociceptive effect than both SalA and
16-Bromo SalA (Figure 3D).
In the intraplantar formaldehyde assay, 16-Ethynyl SalA
(2 mg/kg) had a significant antinociceptive effect from 5
to 10 min, 25 to 45 min, and 60 min, and the 1 mg/kg
dose had a significant effect at 25–35 min compared to the
vehicle/formaldehyde treatment (Figure 4A). Area under the
curve analysis for phase I and phase II pain-related behavior
showed 16-Ethynyl SalA reduced the pain-related behavioral
scores at 2 mg/kg but not 1 mg/kg and nor-BNI significantly
reversed the effect of the 2 mg/kg dose (Figures 4B,C).
A 16-Bromo SalA was tested via i.p. administration in
the intraplantar formaldehyde model. Over the time course,
the 2 mg/kg dose of 16-Bromo SalA reduced pain-related
behavioral scores at 30 min and the 1 mg/kg dose reduced
pain-related behavioral scores at 25 and 30 min (Figure 4D).
16-Bromo SalA did not show a significant reduction in phase I
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(Figure 4E) or phase II pain-related behavioral scores (Figure 4F)
for either dose.
Due to the significant effects of 16-Ethynyl SalA via i.p.
administration in the intraplantar formaldehyde model, the
compound was also tested via i.pl. administration. Figure 5
shows that 16-Ethynyl SalA have antinociceptive effects when
administered locally within the same paw as 2% formaldehyde.
SalA (2 mg/kg i.pl.) and 16-Ethynyl SalA reduced the pain-related
behavioral scores between 5 and 60 min. In the area under the
curve analysis, SalA and 16-Ethynyl SalA reduced both phases of
pain-related behavior (Figures 5B,C).
The rotarod performance test measures motor coordination
and is frequently used to assess the sedative effects of novel drugs.
16-Ethynyl SalA and 16-Bromo SalA were compared to SalA
(2 mg/kg i.p.), which is known to cause motor incoordination
in the rotarod performance test in mice (Kivell et al., 2018).
The time course showed that 16-Ethynyl SalA decreased latency
to fall between 15 and 30 min (Figure 6A). At the 15 min
time point, SalA was more sedative than both doses of 16Ethynyl SalA. Similarly, 16-Bromo SalA had sedative effects
at 15–30 min at the 1 mg/kg dose only (Figure 6B). Both
doses of 16-Bromo SalA were less sedative than SalA at the
15 min time point.
The anxiogenic effects of 16-Ethynyl SalA and 16-Bromo
SalA were evaluated using the elevated zero maze and marble
burying tests. SalA (2 mg/kg i.p.) and 16-Ethynyl SalA (1–
2 mg/kg i.p.) reduced the time in open area, open arm entries and
number of head dips compared to vehicle, whereas, 16-Bromo
SalA (1–2 mg/kg i.p.) did not have any effect (Figures 7A–C).
Marble burying was used to measure anxiogenic and obsessive
compulsive-like behaviors (Figure 7D). Compared to vehicle,
the mice administered SalA (2 mg/kg i.p.) had an increase in
the percentage of marble buried, whereas 16-Ethynyl SalA (1–
2 mg/kg i.p.) and 16-Bromo SalA (1–2 mg/kg i.p.) did not alter
the number of marbles buried.
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FIGURE 3 | Antinociceptive effects of KOPr agonists in acute thermal pain-related behavioral models. (A) Cumulative dose-response effects of 16-Ethynyl SalA and
16-Bromo SalA in the warm water (50◦ C) tail-withdrawal assay. The maximal possible effect (%MPE) at each dose was calculated as a percentage based on the
pre-treatment baseline latencies. Non-linear regression analysis showed 16-Ethynyl SalA and 16-Bromo SalA both exerted antinociceptive effects (n = 6). (B,C) The
warm water (50◦ C) tail-withdrawal latencies were measured over a time course, up to 120 min (n = 7). (B) 16-Ethynyl SalA showed a significant effect up to 15 min
for the 1 mg/kg dose and 60 min for the 2 mg/kg dose. (C) 16-Bromo SalA showed a significant duration of action for up to 60 min. (D) The %MPE of the paw
withdrawal time on the hot-plate (50◦ C) was calculated based on pre-treatment baseline latencies (n = 6). Mice were treated with either vehicle, SalA (2 mg/kg),
16-Ethynyl SalA (2 mg/kg) or 16-Bromo SalA (2 mg/kg) and the withdrawal latencies measured up to 60 min. All compounds had a duration of action of 30 min, and
16-Ethynl SalA was more potent than SalA and 16-Bromo SalA at the 30 min time point. Two-way repeated-measures ANOVA followed by Bonferroni post-tests.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 for 2 mg/kg doses vs. vehicle control. # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001 for 1 mg/kg doses
vs. vehicle control. ∧∧∧ p < 0.001 for 16-Ethynyl SalA vs. both SalA and 16-Bromo SalA. Values presented as mean ± SEM.

0.040 ± 0.010 nM, respectively) and was more potent than SalA
(EC50 = 0.030 ± 0.004 nM) and U69,593 (EC50 = 0.80 ± 0.40 nM)
(Riley et al., 2014). In the current study, 16-Ethynyl SalA and
16-Bromo SalA were more potent than U50,488 in inhibiting
forskolin-stimulated cAMP accumulation. However, 16-Bromo
SalA was less potent in β-arrestin recruitment assays. Thus,
16-Bromo SalA was revealed to be G-protein biased, whereas
16-Ethynyl SalA displayed balanced signaling. It has been
hypothesized, that β-arrestin recruitment is responsible for many
KOPr-mediated adverse effects (Phillips et al., 2013; Zhou et al.,
2013). In support of this, the biased agonist RB-64, showed
no sedation, motor incoordination, or anhedonia-like effects
in mice (White et al., 2015) and the only clinically available
KOPr agonist, nalfurafine, has been shown to be extremely
G-protein biased (Schattauer et al., 2017). However, few reports
have fully explored biased signaling at KOPr and correlated this
to antinociceptive effects and side effects in structurally similar

DISCUSSION
In this study we compared two C-16 analogs of SalA with varying
G-protein biased signaling properties. We showed that 16-Bromo
SalA displayed G-protein biased signaling at KOPr, whereas, 16Ethynyl SalA displayed balanced signaling properties at KOPr.
A 16-Bromo SalA has previously been shown to have a similar
binding affinity for the KOPr to that of SalA and U50,488 (16Bromo SalA Ki = 2.9 ± 0.3 nM; SalA Ki = 2.5 ± 0.6 nM;
U50,488 Ki = 2.2 ± 0.2 nM; in CHO cells stably expressing
hKOPr with [3 H]diprenorphine as the radioligand), as well as
similar potency (16-Bromo SalA EC50 = 2.4 ± 0.2 nM; SalA
EC50 = 2.1 ± 0.6 nM; U50,488 EC50 = 2.9 ± 0.2 nM; measured
with the [35 S]GTP-γ-S functional assay in CHO cells stably
expressing the hKOPr) (Beguin et al., 2009). In cellular assays
(HitHunterTM ), 16-Ethynyl SalA displayed a 2-fold increase in
potency at KOPr compared to 16-Bromo SalA (0.019 ± 0.004 and
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FIGURE 4 | Antinociceptive effect of 16-Ethynyl SalA and 16-Bromo SalA in the intraplantar 2% formaldehyde test. (A) Time course of pain-related behavior
following intraplantar 2% formaldehyde injection into the right hind paw. 16-Ethynyl SalA (1–2 mg/kg i.p.) treatment showed a significant reduction in pain-related
behavior compared to the vehicle/formaldehyde-treated control group. (B,C) The area under the curve (AUC) was calculated for phase I nociceptive pain-related
behavior (0–15 min, B) and phase II inflammatory pain-related behavior (20–60 min, C). 16-Ethynyl SalA showed a significant reduction in both phases compared to
the vehicle/formaldehyde treatment, which was reversed using the KOPr antagonist nor-binaltorphimine (nor-BNI). (D) Time course of pain-related behavior for
16-Bromo SalA (1–2 mg/kg i.p.) treatment showed a significant reduction in pain-related behavior compared to the vehicle/formaldehyde-treated positive control
group. (E,F) AUC for phase I nociceptive pain-related behavior (0–15 min, E) and phase II inflammatory pain-related behavior (20–60 min, F). 16-Bromo SalA did not
show a significant reduction in both phases of pain-related behavior compared to the vehicle/formaldehyde control group. (A,D) Two-way repeated-measures
ANOVA with Bonferroni post-tests. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 for 2 mg/kg dose vs. vehicle/formaldehyde control. # p < 0.05, ## p < 0.01,
### p < 0.001 for 1 mg/kg dose vs. vehicle/formaldehyde control. ∧ p < 0.05, ∧∧ p < 0.01, ∧∧∧ p < 0.001, ∧∧∧∧ p < 0.0001 for comparison between the 2 mg/kg
with and without nor-BNI pre-treatment. (B,C,E,F) Kruskal–Wallis test with Dunn’s post-tests. Values presented as mean ± SEM, n = 6–7 and n = 5 for nor-BNI
antagonist group. Number in brackets indicates dose in mg/kg and F = formaldehyde i.pl. administration.

agonists (DiMattio et al., 2015; White et al., 2015; Dunn et al.,
2018, 2019; Ho et al., 2018; Kaski et al., 2019; Mores et al., 2019).
In addition, a recent paper showed low intrinsic efficacy, rather
than G-protein bias, could explain the reduced respiratory side
effects in MOPr agonists (Gillis et al., 2020).
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of SalA, the antinociceptive effects were measured in thermal
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effects in the warm water tail-withdrawal assay show that
both 16-Ethynyl SalA and 16-Bromo SalA had increased
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FIGURE 5 | Local adminstration of 16-Ethynyl SalA produced antinocieptive effects in the intraplantar 2% formaldehyde assay. (A) Time course of pain-related
behavior following intraplantar 2% formaldehyde injection into the right hind paw. 16-Ethynyl SalA (2 mg/kg i.pl.) treatment showed a significant reduction in
pain-related behavior compared to the vehicle/formaldehyde-treated control. Two-way repeated-measures ANOVA with Bonferroni post-tests. (B,C) Area under the
curve (AUC) analysis of phase I (B) and II (C) pain-related behaviors. 16-Ethynyl SalA reduced both phases of pain-related behavior. Kruskal–Wallis test with Dunn’s
post-tests. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 for 2 mg/kg doses vs. vehicle/formaldehyde control. Values presented as mean ± SEM, n = 6.
Number in brackets indicates dose in mg/kg and F = formaldehyde i.pl. administration.

FIGURE 6 | KOPr agonists cause motor incoordination in the rotarod performance assay. Using a rotarod apparatus set to accelerate from 4 to 40 rpm over 300 s,
SalA showed a significant effect at 15–30 min. (A) 16-Ethynyl showed a significant effect at 15–30 min. (B) 16-Bromo SalA had a significant impairment at 15–30 min
at 1 mg/kg. Two-way repeated-measures ANOVA, **p < 0.01, ****p < 0.0001 for 2 mg/kg dose (above) or SalA (below) vs. vehicle. # p < 0.05, ### p < 0.001 for
1 mg/kg dose vs. vehicle. ∧ indicates time point where SalA is more sedative than both doses of the novel analog. Values presented as mean ± SEM, n = 6.
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FIGURE 7 | Biased agonist 16-Bromo SalA does not have anxiogenic side effects compared to balanced agonist 16-Ethynyl SalA. Mice were tested on the elevated
zero maze for 5 min with recordings made for the (A) time in the open area, (B) the number of open entries, and (C) number of head dips. SalA (2 mg/kg i.p.) and
16-Ethynyl SalA (1–2 mg/kg i.p.) reduced the all the behaviors, whereas, 16-Bromo SalA (1–2 mg/kg i.p.) had no effect. (D) The marble-burying experiment showed
SalA administration lead to a significant increase in the percentage of marbles buried, whereas, the novel analogs did not alter the marble count. One-way ANOVA
with Bonferroni post-tests. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared to vehicle control. Values presented as mean ± SEM, n = 8.

of the novel analogs indicate that these structural modifications
have improved pharmacokinetic profiles as these analogs were
designed to decrease the metabolism of the furan ring of the
SalA scaffold (Riley et al., 2014). C-2 alterations of the SalA
structure, such as the analog ethoxymethyl ether (EOM) SalB,
are more metabolically stable (Ewald et al., 2017). While less is
known about the effects of C-16 alterations, it has been predicted
that modifications at the C-16 position may hinder the action
of cytochrome P450 enzymes (Wilson et al., 1990). Since the
short duration of action of SalA is one factor that has limited the
clinical development of SalA analogs agonists, the increase in the
duration for the novel analogs is a promising development.
The antinociceptive effects of the KOPr agonists were further
assessed using the intraplantar formaldehyde model of both
nociceptive and inflammatory pain. The i.p. administration of
16-Ethynyl SalA produced antinociceptive effects in phase I at
2 mg/kg and in phase II at both 1 and 2 mg/kg doses, which was
prevented by administration of the KOPr antagonist nor-BNI. 16Bromo SalA did not reduce phase I nor phase II overall, however,
did have a significant effect at the 25–30 min time point when
time-course data was analyzed. Aviello et al. (2011) hypothesized

potency compared to U50,488. This effect mirrors the increased
potency of the novel analogs in G-protein signaling pathway
compared to U50,488.
One of the limitations of SalA is that it is rapidly metabolized
to the inactive Salvinorin B, and therefore the antinociceptive
effects of SalA are short-acting (Butelman et al., 2009; Teksin
et al., 2009; Ranganathan et al., 2012). Because of this known
limitation, we evaluated the antinociceptive duration of action
of the SalA analogs in warm water tail-withdrawal and hot-plate
assays. We have previously shown SalA to have a duration of
30 min in our model (Paton et al., 2017) while McCurdy et al.
(2006) found that SalA (2–4 mg/kg) had a duration of action
of 20 min in the tail-withdrawal assay and 10 min in the hotplate (52◦ C) assay in male Swiss mice. 16-Ethynyl SalA (2 mg/kg)
had a longer duration of action with significant antinociception
at 5–60 min. 16-Bromo SalA (2 mg/kg) had a slower onset
of action, with significant effects at 10–60 min. Similar effects
were observed in the hot-plate test with all compounds having
antinociceptive effect up to 30 min. In addition, 16-Ethynyl
SalA had greater antinociceptive effect than SalA and 16-Bromo
SalA at the 30 min time point. The longer duration of action
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important to consider the effect of locomotor activity, as the
motor incoordination could indicate that the mice would have
impaired locomotor activity. However, this does not appear to
be the case in the marble burying task, as SalA, which produced
significant motor incoordination compared to the novel analogs,
lead to an increase in the number of marbles buried. Overall, 16Bromo SalA but not 16-Ethynyl SalA had no observed anxiogenic
side effects, which is an improvement over SalA, and does
correlate with the theory of G-protein bias agonists having fewer
side effects. However, 16-Bromo SalA was also less potent in the
pain-related behavioral models, which could explain a lack of
potency in the side effects also. Further work is warranted to fully
understand any other KOPr-mediated side effects such as aversive
and depressive-like effects.
Overall, 16-Ethynyl SalA had significant antinociceptive
effects in acute nociceptive and inflammatory pain models and
had reduced side effects compared to the parent compound SalA.
16-Bromo SalA reduced some pain-related behaviors and did not
show any anxiogenic side effects.

that higher doses of SalA (2 mg/kg) may have a central target,
whilst lower doses (0.5 mg/kg) appeared to have a peripheral
effect greater than the central effects. In the present study, 16Ethynyl SalA was also administered via i.pl. injection at the site
of inflammation, to assess local effects. At 2 mg/kg SalA reduced
pain-related behavioral scores and reduced both phase I and II
pain-related behavioral scores following AUC analysis. Similarly,
16-Ethynyl SalA was effective at reducing both phases of painrelated behavior. Overall, 16-Ethynyl SalA was shown to be more
effective at reducing nociceptive and inflammatory pain-related
behavior. However, it would be worth further exploring the effects
of these compounds in pain-depressed behavioral models, such
as models that measure a decrease in the level of feeding or
locomotor activity when animals are in a pain-like state (Negus
et al., 2010). These models avoid the false positive outcomes that
can occur in pain-stimulated behavioral models when drugs have
sedative effects (Negus, 2019).
Kappa opioid receptor agonists, including SalA have
previously been shown to have sedative effects. White et al.
(2015) found that SalA induced motor incoordination in the
rotarod performance test for up to 30 min at doses between
3 and 10 mg/kg in both female and male C57BL/6J mice,
whereas the G-protein biased agonist, RB-64, did not cause any
motor deficits. In male NIH Swiss mice, SalA (0.5–2 mg/kg)
disrupted climbing behavior in the inverted screen task, a
model of motor coordination, with the effect lasting only
5 min, compared to U69,593 (1 mg/kg) for which the effects
lasted 10 min (Fantegrossi et al., 2005). We have previously
shown in Sprague–Dawley rats, that 16-Bromo SalA (1 mg/kg)
and 16-Ethynyl SalA (0.3–2 mg/kg) did not have an effect on
spontaneous locomotor activity (Riley et al., 2014; Mathew,
2019). In the present study, the effects of the KOPr agonists on
motor coordination were measured over 240 min, and SalA,
16-Ethynyl SalA and 16-Bromo SalA were found to have sedative
effects for up to 30 min. SalA had a longer duration than we
have previously reported (Kivell et al., 2018); however, the
previous study used a rotarod at a set-speed (16 rpm), whereas
the current study used an accelerating procedure, which better
measures motor coordination (Deacon, 2013). Interestingly,
at the 15 min time point, SalA was more sedative than both
16-Ethynyl SalA and 16-Bromo SalA, showing the novel analogs
have an improvement over SalA.
Salvinorin A has anxiogenic side effects mediated by the KOPr
system (Braida et al., 2009), and in particular, we have previously
shown that SalA has anxiogenic effects in the elevated plus maze
in rats (Ewald et al., 2017). In the current study, we chose to test
two models of anxiety in mice to get a better understanding of
this complex side-effect. The elevated zero maze measures the
conflict between exploratory behaviors and the avoidance of open
and elevated areas (Shepherd et al., 1994), whereas, the marble
burying test measures a repetitive, compulsive behavior triggered
by anxiety (Broekkamp et al., 1986). In the elevated zero maze,
SalA reduced the time in the open area, the number of open
entries and number of head dips with 16-Ethynyl SalA having
similar effects, whereas, 16-Bromo SalA had no effect. Similarly,
the marble-burying experiment showed SalA administration lead
to a significant increase in the percentage of marbles buried,
while the novel analogs did not alter the marble count. It is
Frontiers in Neuroscience | www.frontiersin.org
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